Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease

Clinical and Experimental Dermatology

Volumn 40, Issue 7, 2015, Pages 722-727

  Abedini, R ^a   Salehi, M ^a   Lajevardi, V ^a   Beygi, S ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b National Elites Foundation of Iran   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; IRANIAN PEOPLE; LIPOPROTEIN BLOOD LEVEL; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PSORIASIS; PSORIASIS ACTIVITY AND SEVERITY INDEX; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; AGED; CASE CONTROL STUDY; COMPLICATION; IRAN; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; HUMANS; IRAN; LOGISTIC MODELS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; PSORIASIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84941740586     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/ced.12672     Document Type: Article

References (25)

1. Weigle N, McBane S,. Psoriasis. Am Fam Physician 2013; 87: 626-33.
2. Parisi R, Symmons DP, Griffiths CE, et al., Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-85.
3. Gisondi P, Girolomoni G,. Cardiometabolic comorbidities and the approach to patients with psoriasis. Actas Dermosifiliogr 2009; 100 (Suppl): 14-21.
4. Gisondi P, Ferrazzi A, Girolomoni G,. Metabolic comorbidities and psoriasis. Acta Dermatovenerol Croat 2010; 18: 297-304.
5. Gisondi P, Del Giglio M, Cozzi A, et al., Psoriasis, the liver, and the gastrointestinal tract. Dermatol Ther 2010; 23: 155-9.
6. Angulo P,. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
7. Masuoka HC, Chalasani N,. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci 2013; 1281: 106-22.
8. Wenk KS, Arrington KC, Ehrlich A,. Psoriasis and non-alcoholic fatty liver disease. J Eur Acad Dermatol Venereol 2011; 25: 383-91.
9. Gisondi P, Targher G, Zoppini G, et al., Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 758-64.
10. Bordignon M, Viel G, Peserico A, et al., Non-alcoholic fatty liver disease, alcohol intake and psoriasis. J Hepatol 2010; 53: 587.
11. Obika M, Noguchi H,. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res 2012; 2012: 145754.
12. Hernaez R, Lazo M, Bonekamp S, et al., Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54: 1082-90.
13. Samson SL, Garber AJ,. Metabolic syndrome. Endocrinol Metab Clin North Am 2014; 43: 1-23.
14. Eshraghian A, Dabbaghmanesh MH, Eshraghian H, et al., Nonalcoholic fatty liver disease in a cluster of Iranian population: thyroid status and metabolic risk factors. Arch Iran Med 2013; 16: 584-9.
15. Lankarani KB, Ghaffarpasand F, Mahmoodi M, et al., Non alcoholic fatty liver disease in southern Iran: a population based study. Hepat Mon 2013; 13: e9248.
16. Lonardo A, Loria P, Carulli N,. Concurrent non-alcoholic steatohepatitis 16and psoriasis. Report of three cases from the POLI.ST.E.N.A. study. Dig Liver Dis 2001; 33: 86-7.
17. Matsumoto T, Suzuki N, Watanabe H, et al., Nonalcoholic steatohepatitis associated with psoriasis vulgaris. J Gastroenterol 2004; 39: 1102-5.
18. Miele L, Vallone S, Cefalo C, et al., Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 778-86.
19. Madanagobalane S, Anandan S,. The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India. Australas J Dermatol 2012; 53: 190-7.
20. Beygi S, Lajevardi V, Abedini R,. C-reactive protein in psoriasis: a review of the literature. J Eur Acad Dermatol Venereol 2014; 28: 700-11.
21. Zein CO, Unalp A, Colvin R, et al., Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol 2011; 54: 753-9.
22. Hamabe A, Uto H, Imamura Y, et al., Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period. J Gastroenterol 2011; 46: 769-78.
23. Galal O,. Nutrition-related health patterns in the Middle East. Asia Pac J Clin Nutr 2003; 12: 337-43.
24. Delavari A, Forouzanfar MH, Alikhani S, et al., First nationwide study of the prevalence of the metabolic syndrome and optimal cutoff points of waist circumference in the Middle East: the national survey of risk factors for noncommunicable diseases of Iran. Diabetes Care 2009; 32: 1092-7.
25. Azizi F, Mirmiran P, Momenan AA, et al., The effect of community-based education for lifestyle intervention on the prevalence of metabolic syndrome and its components: Tehran lipid and glucose study. Int J Endocrinol Metab 2013; 11: 145-53.